Progress and Perspectives in the Development of Lentiviral Vector Producer Cells

Mariana V. Ferreira, Elisa T. Cabral, Ana Sofia Coroadinha

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)

Abstract

After two decades of clinical trials, gene therapy demonstrated effectiveness in the treatment of a series of diseases. Currently, several gene therapy products are approved and used in the clinic. Lentiviral vectors (LVs) are one of the most used transfer vehicles to deliver genetic material and the vector of choice to modify hematopoietic cells to correct primary immunodeficiencies, hemoglobinopathies, and leukodystrophies. LVs are also widely used to modify T cells to treat cancers in immunotherapies (e.g., chimeric antigen receptors T cell therapies, CAR-T). In genome editing, LVs are used to deliver sequence-specific designer nucleases and DNA templates. The approval LV gene therapy products (e.g., Kymriah, for B-cell Acute lymphoblastic leukemia treatment; LentiGlobin, for β-thalassemia treatment) reinforced the need to improve their bioprocess manufacturing. The production has been mostly dependent on transient transfection. Production from stable cell lines facilitate GMP compliant processes, providing an easier scale-up, reproducibility and cost-effectiveness. The establishment of stable LV producer cell lines presents, however, several difficulties, with the cytotoxicity of some of the vector proteins being a major challenge. Genome editing technologies pose additional challenges to LV producer cells. Herein the major bottlenecks, recent achievements, and perspectives in the development of LV stable cell lines are revised.

Original languageEnglish
Article number2000017
JournalBiotechnology Journal
Volume16
Issue number1
DOIs
Publication statusPublished - 2020

Keywords

  • gene therapy
  • genome editing
  • lentiviral vectors
  • packaging cells
  • producer cells

Fingerprint

Dive into the research topics of 'Progress and Perspectives in the Development of Lentiviral Vector Producer Cells'. Together they form a unique fingerprint.

Cite this